Sun Pharmaceutical Industries Inc. announces results from their five-year Phase-3 efficacy and safety clinical trial for ILUMYA®(tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension.
Stay informed Join the email list to receive the latest information on psoriasis meetings, manuscripts and research. SUBSCRIBE now available COVID-19 Psoriasis Resource Center Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve explore now
Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve